US-China Biomedical Technology, Inc. operates as an early stage biomedical technology and services company.
Mediocre balance sheet with weak fundamentals.
- US-China Biomedical Technology has significant price volatility in the past 3 months.
- US-China Biomedical Technology is not covered by any analysts.
Share Price & News
How has US-China Biomedical Technology's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
UCBB underperformed the Healthcare industry which returned -8.4% over the past year.
UCBB underperformed the Market in United States of America which returned 1.9% over the past year.
Share holder returns
Price Volatility Vs. Market
How volatile is US-China Biomedical Technology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is US-China Biomedical Technology undervalued based on future cash flows and its price relative to the stock market?
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for US-China Biomedical Technology to establish if it is available at moderate discount.
Unable to calculate intrinsic value for US-China Biomedical Technology to establish if it is available at substantial discount.
Price Based on Earnings
US-China Biomedical Technology is loss making, we can't compare its value to the US Healthcare industry average.
US-China Biomedical Technology is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for US-China Biomedical Technology, we can't assess if its growth is good value.
Price Based on Value of Assets
US-China Biomedical Technology is overvalued based on assets compared to the US Healthcare industry average.
How is US-China Biomedical Technology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as US-China Biomedical Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of UCBB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access US-China Biomedical Technology's filings and announcements here.
- Explore growth companies in the Healthcare industry.
How has US-China Biomedical Technology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
US-China Biomedical Technology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare US-China Biomedical Technology's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare US-China Biomedical Technology's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if US-China Biomedical Technology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if US-China Biomedical Technology has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if US-China Biomedical Technology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
How is US-China Biomedical Technology's financial position?
Financial Position Analysis
US-China Biomedical Technology's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
US-China Biomedical Technology's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
US-China Biomedical Technology has no debt.
US-China Biomedical Technology currently has no debt however we can't compare to 5 years ago as we have no data for that period.
High level of physical assets or inventory.
US-China Biomedical Technology has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
US-China Biomedical Technology has less than a year of cash runway based on current free cash flow.
US-China Biomedical Technology has less than a year of cash runway if free cash flow continues to grow at historical rates of 70.2% each year.
What is US-China Biomedical Technology's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate US-China Biomedical Technology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate US-China Biomedical Technology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as US-China Biomedical Technology has not reported any payouts.
Unable to verify if US-China Biomedical Technology's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as US-China Biomedical Technology has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
What is the CEO of US-China Biomedical Technology's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Sunny Huang (45yo)
Mr. Qingxi Huang, also known as Sunny, has been Chief Executive Officer, Chief Financial Officer, President, Secretary and Treasurer of Cloud Security Corporation since November 28, 2017. Mr. Huang serves ...
Management Age and Tenure
The average tenure for the US-China Biomedical Technology management team is over 5 years, this suggests they are a seasoned and experienced team.
No 3 month open market individual insider trading information.
Recent Insider Transactions
Chief Executive Officer
- Tenure: 20.7yrs
- Tenure: 20.7yrs
Sunny Huang (45yo)
- Tenure: 1.8yrs
Safa Movassagi (57yo)
- Tenure: 0.5yrs
- Compensation: US$54.55k
Sunny Huang (45yo)
- Tenure: 1.8yrs
US-China Biomedical Technology, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: US-China Biomedical Technology, Inc.
- Ticker: UCBB
- Exchange: OTCPK
- Founded: 2010
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$535.056k
- Shares outstanding: 19.82m
- Website: https://www.ucbb.us
Number of Employees
- US-China Biomedical Technology, Inc.
- 2 Park Plaza
- Suite 400
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UCBB||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||May 2012|
US-China Biomedical Technology, Inc. operates as an early stage biomedical technology and services company. The company was formerly known as Cloud Security Corporation and changed its name to US-China Bio ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/09/19 00:11|
|End of Day Share Price||2019/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.